Medherant’s Year in Review – 2018

Last year was another busy year for Medherant with a significant milestone reached when we received positive results from the first clinical trials with our TEPI Patch® technology. We also received grant funding to develop plans for our own GMP manufacturing facility, filed patent applications for new adhesives, and expanded our team. Here are some of our highlights from 2018.

Progress of the TEPI Patch

We completed two Phase I clinical trials in November with our most advanced TEPI Patch product, the Ibuprofen TEPI Patch. The novel adhesive was shown to be well tolerated by all subjects in a study of skin irritation and sensitisation, giving us the confidence to develop the next generation of drug-in-adhesive patches. As expected, the second study showed that blood levels of ibuprofen were significantly lower after repeated application of the patch compared to a single oral dose. Local application of ibuprofen will provide site-specific pain relief and avoid gastro-intestinal irritation, and a lower blood concentration will help minimise side effects. We have developed plans to extend our small scale manufacture of TEPI Patches for non-clinical studies to GMP manufacture of patches for clinical trial. The design work was supported by the award of a Medicines Manufacturing Grant from Innovate UK. Having our own in-house GMP manufacturing capability would make process optimisation more efficient and reduce costs, as well as allowing us to retain our know how.

New team members

We were pleased to welcome James Robson and Lucy Brindle to the Medherant team, who both bring a wealth of experience in the pharmaceutical industry. James Robson joined the company in July 2018 as CFO, bringing with him 27 years’ experience in the pharmaceutical and healthcare industries. Alongside Medherant he supports other innovative start-ups and growth companies in the pharmaceutical, healthcare and medtech sectors to develop, fund and execute their financial business plans. He is a Chartered Management Accountant and holds a degree in Chemical Engineering from the University of Birmingham. Lucy Brindle worked with Medherant as a freelance clinical project manager before joining the Company permanently in December 2018 as Head of Programme Management and Clinical Development. She has over 15 years’ clinical research experience, working for pharma, CROs and academia. Lucy has worked in all phases of clinical development across a wide range of therapeutic areas and technologies.

We look forward to continuing this exciting progress in 2019 by advancing the development of a pipeline of TEPI Patch products, one containing an approved cannabinoid (dronabinol) for chemotherapy-induced nausea and vomiting, and two patches to treat Alzheimer’s disease, containing memantine and donepezil.